Improved Alertness Is Associated with Early Increase in Serum Brain-Derived Neurotrophic Factor and Antidepressant Treatment Outcome in Major Depression

Neuropsychobiology

Volumn 72, Issue 1, 2015, Pages 16-28

  Mikoteit, Thorsten ^a   Hemmeter, Ulrich ^e   Eckert, Anne ^b   Brand, Serge ^a,c   Bischof, Roland ^d   Delini Stula, Alexandra ^d   Holsboer Trachsler, Edith ^a   Beck, Johannes ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d ADI Int Institute for Advancement of Drug Development GmbH   (Switzerland)

^e Center of Education and Research COEUR   (Switzerland)

Author keywords

Alertness; Antidepressants; Brain derived neurotrophic factor; Cognitive function; Duloxetine; Major depression; Serotonin norepinephrine reuptake inhibitor; Treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; ANTIDEPRESSANT AGENT;

ADULT; ALERTNESS; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; WORKING MEMORY; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; SHORT TERM MEMORY;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84940740084     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000437439     Document Type: Article

References (90)

1. Castaneda AE, Tuulio-Henriksson A, Marttunen M, Suvisaari J, Lonnqvist J: A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J Affect Disord 2008; 106: 1-27.
2. Kaymak SU, Demir B, Senturk S, Tatar I, Aldur MM, Ulu B: Hippocampus, glucocorticoids and neurocognitive functions in patients with first-episode major depressive disorders. Eur Arch Psychiatry Clin Neurosci 2010; 260: 217-223.
3. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA: A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord 2012; 140: 113-124.
4. McClintock SM, Husain MM, Greer TL, Cullum CM: Association between depression severity and neurocognitive function in major depressive disorder: A review and synthesis. Neuropsychology 2010; 24: 9-34.
5. Porter RJ, Bourke C, Gallagher P: Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust NZ J Psychiatry 2007; 41: 115-128.
6. Den Hartog HM, Derix MM, Van Bemmel AL, Kremer B, Jolles J: Cognitive functioning in young and middle-aged unmedicated outpatients with major depression: Testing the effort and cognitive speed hypotheses. Psychol Med 2003; 33: 1443-1451.
7. Farrin L, Hull L, Unwin C, Wykes T, David A: Effects of depressed mood on objective and subjective measures of attention. J Neuropsychiatry Clin Neurosci 2003; 15: 98-104.
8. Majer M, Ising M, Kunzel H, Binder EB, Holsboer F, Modell S, Zihl J: Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med 2004; 34: 1453-1463.
9. Oral E, Canpolat S, Yildirim S, Gulec M, Aliyev E, Aydin N: Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res Bull 2012; 88: 454-459.
10. Snyder HR: Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review. Psychol Bull 2013; 139: 81-132.
11. Douglas KM, Porter RJ: Longitudinal assessment of neuropsychological function in major depression. Aust NZ J Psychiatry 2009; 43: 1105-1117.
12. Hasselbalch BJ, Knorr U, Kessing LV: Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. J Affect Disord 2011; 134: 20-31.
13. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV: Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology 2012; 26: 642-651.
14. Paelecke-Habermann Y, Pohl J, Leplow B: Attention and executive functions in remitted major depression patients. J Affect Disord 2005; 89: 125-135.
15. Reppermund S, Ising M, Lucae S, Zihl J: Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med 2009; 39: 603-614.
16. Jaeger J, Berns S, Uzelac S, Davis-Conway S: Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006; 145: 39-48.
17. Elgamal S, Denburg S, Marriott M, MacQueen G: Clinical factors that predict cognitive function in patients with major depression. Can J Psychiatry 2010; 55: 653-661.
18. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV: The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur Psychiatry 2013; 28: 349-355.
19. Bhalla RK, Butters MA, Becker JT, Houck PR, Snitz BE, Lopez OL, Aizenstein HJ, Raina KD, DeKosky ST, Reynolds CF 3rd: Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry 2009; 17: 308-316.
20. Lee JS, Potter GG, Wagner HR, Welsh-Bohmer KA, Steffens DC: Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr 2007; 19: 125-135.
21. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Imbimbo BP, Santamato A, Vendemiale G, Seripa D, Pilotto A, Capurso A, Solfrizzi V: Late-life depression, mild cognitive impairment, and dementia: Possible continuum? Am J Geriatr Psychiatry 2010; 18: 98-116.
22. Constant EL, Adam S, Gillain B, Seron X, Bruyer R, Seghers A: Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety 2005; 21: 78-89.
23. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, Herrera-Guzman D, Gomez-Carbajal L, Pena-Olvira M, Villuendas-Gonzalez E, Joan GO: Effects of selective serotonin reuptake and dual serotonergicnoradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 2010; 177: 323-329.
24. Etkin A, Patenaude B, Song YJ, Usherwood T, Rekshan W, Schatzberg AF, Rush AJ, Williams LM: A cognitive-emotional biomarker for predicting remission with antidepressant medications: A report from the iSPOT-D Trial. Neuropsychopharmacology 2015; 40: 1332-1342.
25. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, Stewart JW, Zalsman G, Mann JJ: Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm 2008; 115: 1213-1219.
26. Kampf-Sherf O, Zlotogorski Z, Gilboa A, Speedie L, Lereya J, Rosca P, Shavit Y: Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. J Affect Disord 2004; 82: 453-459.
27. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F: Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005; 58: 204-210.
28. Baldwin R, Jeffries S, Jackson A, Sutcliffe C, Thacker N, Scott M, Burns A: Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med 2004; 4: 125-136.
29. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S: Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 2000; 60: 13-23.
30. Marcos T, Portella MJ, Navarro V, Gasto C, Rami L, Lazaro L, Salamero M: Neuropsychological prediction of recovery in late-onset major depression. Int J Geriatr Psychiatry 2005; 20: 790-795.
31. Pimontel MA, Culang-Reinlieb ME, Morimoto SS, Sneed JR: Executive dysfunction and treatment response in late-life depression. Int J Geriatr Psychiatry 2012; 27: 893-899.
32. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM: Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 2006; 163: 73-78.
33. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
34. Hallbook F: Evolution of the vertebrate neurotrophin and Trk receptor gene families. Curr Opin Neurobiol 1999; 9: 616-621.
35. Dijkhuizen PA, Ghosh A: BDNF regulates primary dendrite formation in cortical neurons via the PI3-kinase and MAP kinase signaling pathways. J Neurobiol 2005; 62: 278-288.
36. Gorski JA, Zeiler SR, Tamowski S, Jones KR: Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 2003; 23: 6856-6865.
37. Lu B, Chow A: Neurotrophins and hippocampal synaptic transmission and plasticity. J Neurosci Res 1999; 58: 76-87.
38. Bramham CR, Messaoudi E: BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis. Prog Neurobiol 2005; 76: 99-125.
39. Lu B, Nagappan G, Lu Y: BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol 2014; 220: 223-250.
40. Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-1180.
41. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM: Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 2014; 19: 791-800.
42. Sen S, Duman R, Sanacora G: Serum brainderived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
43. Brunoni AR, Machado-Vieira R, Zarate CA Jr, Vieira EL, Vanderhasselt MA, Nitsche MA, Valiengo L, Bensenor IM, Lotufo PA, Gattaz WF, Teixeira AL: BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial. Eur Neuropsychopharmacol 2014; 24: 1144-1151.
44. Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R: Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry 2013; 46: 54-58.
45. Gedge L, Beaudoin A, Lazowski L, du Toit R, Jokic R, Milev R: Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. Front Psychiatry 2012; 3: 12.
46. Haghighi M, Salehi I, Erfani P, Jahangard L, Bajoghli H, Holsboer-Trachsler E, Brand S: Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 2013; 47: 908-915.
47. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M: Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008; 41: 66-71.
48. Lang UE, Hellweg R, Gallinat J, Bajbouj M: Acute prefrontal cortex transcranial magnetic stimulation in healthy volunteers: no effects on brain-derived neurotrophic factor (BDNF) concentrations in serum. J Affect Disord 2008; 107: 255-258.
49. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC: Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009; 43: 247-254.
50. Mikoteit T, Beck J, Eckert A, Hemmeter U, Brand S, Bischof R, Holsboer-Trachsler E, Delini-Stula A: High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. Psychopharmacology (Berl) 2014; 231: 2955-2965.
51. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN: Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447-458.
52. Komulainen P, Pedersen M, Hanninen T, Bruunsgaard H, Lakka TA, Kivipelto M, Hassinen M, Rauramaa TH, Pedersen BK, Rauramaa R: BDNF is a novel marker of cognitive function in ageing women: The DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 596-603.
53. Yu H, Zhang Z, Shi Y, Bai F, Xie C, Qian Y, Yuan Y, Deng L: Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J Clin Psychiatry 2008; 69: 1104-1111.
54. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K: Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006; 113: 1217-1124.
55. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T: Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 2011; 14: 399-404.
56. Patanella AK, Zinno M, Quaranta D, Nociti V, Frisullo G, Gainotti G, Tonali PA, Batocchi AP, Marra C: Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res 2010; 88: 1106-1112.
57. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer-Sant'anna M, Grassi-Oliveira R, Post RM: Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32: 675-692.
58. World Health Organization: ICD-10 Classification of Mental and Behavioural Disorders with Glossary and Diagnostic Criteria for Research ICD10: DCR-10. Edinburgh, Churchill Livingstone, 1994.
59. Zimmermann P, Fimm B: Testbattery for Attentional Performance (version 2.1) (in German). Herzogenrath, Psychologische Testsysteme, 2007.
60. Kupfer DJ: Management of recurrent depression. J Clin Psychiatry 1993; 54(suppl):29-33.
61. Cohen J: Statistical Power Analysis for the Behavioural Sciences. Hillsdale, Lawrence Erlbaum Associates, 1988.
62. Zhu W: Sadly, the Earth is still round (p < 0.05). J Sport Health Sci 2012; 1: 9-11.
63. Manning KJ, Alexopoulos GS, Banerjee S, Shizuko Morimoto S, Seirup JK, Klimstra SA, Yuen G, Kanellopoulos T, Gunning-Dixon F: Executive functioning complaints and escitalopram treatment response in late-life depression. Am J Geriatr Psychiatry 2015; 23: 440-445.
64. McEwen BS, Stellar E: Stress and the individual mechanisms leading to disease. Arch Intern Med 1993; 153: 2093-2101.
65. Vieta E, Popovic D, Rosa AR, Sole B, Grande I, Frey BN, Martinez-Aran A, Sanchez-Moreno J, Balanza-Martinez V, Tabares-Seisdedos R, Kapczinski F: The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2013; 28: 21-29.
66. Karlamangla AS, Singer BH, Greendale GA, Seeman TE: Increase in epinephrine excretion is associated with cognitive decline in elderly men: MacArthur studies of successful aging. Psychoneuroendocrinology 2005; 30: 453-460.
67. Mohlman J, Gorman JM: The role of executive functioning in CBT: A pilot study with anxious older adults. Behav Res Ther 2005; 43: 447-465.
68. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, Elzinga BM, Voshaar RC: Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228-239.
69. Elzinga BM, Molendijk ML, Oude Voshaar RC, Bus BA, Prickaerts J, Spinhoven P, Penninx BJ: The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl) 2011; 214: 319-328.
70. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetke CZ, Schuff-Werner P, Virchow JC: The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26: 115-123.
71. Tang SW, Chu E, Hui T, Helmeste D, Law C: Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett 2008; 431: 62-65.
72. Jacobsen JP, Mork A: The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004; 1024: 183-192.
73. Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S, Racagni G, Popoli M: Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neurosci 2009; 10: 48.
74. Duman RS, Aghajanian GK: Synaptic dysfunction in depression: Potential therapeutic targets. Science 2012; 338: 68-72.
75. Jourdi H, Hsu YT, Zhou M, Qin Q, Bi X, Baudry M: Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci 2009; 29: 8688-8697.
76. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS: BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 2014; 18:pii.pyu033.
77. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
78. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK: Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012; 71: 996-1005.
79. Giese M, Beck J, Brand S, Muheim F, Hemmeter U, Hatzinger M, Holsboer-Trachsler E, Eckert A: Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. J Psychiatr Res 2014; 59: 1-7.
80. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
81. Gong P, Zheng A, Chen D, Ge W, Lv C, Zhang K, Gao X, Zhang F: Effect of BDNF Val66Met polymorphism on digital working memory and spatial localization in a healthy Chinese Han population. J Mol Neurosci 2009; 38: 250-256.
82. Miyajima F, Ollier W, Mayes A, Jackson A, Thacker N, Rabbitt P, Pendleton N, Horan M, Payton A: Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 2008; 7: 411-417.
83. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr, Morimoto SS, Lim KO, Gunning FM: BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 2010; 125: 262-268.
84. El-Hage W, Vourc'h P, Gaillard P, Leger J, Belzung C, Ibarguen-Vargas Y, Andres CR, Camus V: The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients. Psychopharmacology (Berl) 2015; 232: 575-581.
85. Erickson KI, Banducci SE, Weinstein AM, Macdonald AW 3rd, Ferrell RE, Halder I, Flory JD, Manuck SB: The brain-derived neurotrophic factor Val66Met polymorphism moderates an effect of physical activity on working memory performance. Psychol Sci 2013; 24: 1770-1779.
86. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF: Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010; 20: 535-544.
87. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
88. Stahl SM, Zhang L, Damatarca C, Grady M: Brain circuits determine destiny in depression: A novel approach to psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003; 64(suppl 11):6-17.
89. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE: Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 2009; 43: 855-863.
90. Graf H, Abler B, Hartmann A, Metzger CD, Walter M: Modulation of attention network activation under antidepressant agents in healthy subjects. Int J Neuropsychopharmacol 2013; 16: 1219-1230.